Associated Papers
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study.
Nelson BE et al.
Molecular Cancer, 2024
Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers.
Shah JB et al.
Nature Communications, 2022
36344544 (PubMed )
Supplement: 41467_2022_34523_MOESM5_ESM.xlsx › TP53_Mutations_Comparison
Identification of relevant genetic alterations in cancer using topological data analysis.
Rabadán R et al.
Nature Communications, 2020
32732999 (PubMed )
Supplement: 41467_2020_17659_MOESM3_ESM.xls › TableS1
Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer.
Boyarskikh UA et al.
Frontiers in Oncology, 2020
32766142 (PubMed )
Supplement: Table_2.XLSX › list_of_TP53_mutations
An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer.
Haynes BC et al.
Translational Oncology, 2019
30981944 (PubMed )
Supplement: mmc1.xlsx › S3
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.
Brannon AR et al.
Genome Biology, 2014
25164765 (PubMed )
Supplement: 13059_2014_454_MOESM1_ESM.xlsx › Sheet1
Genomic landscape and actionable mutations of brain metastases derived from non-small cell lung cancer: A systematic review.
Andrews LJ et al.
Neuro-oncology Advances, 0
38130901 (PubMed )
Supplement: vdad145_suppl_supplementary_data.xlsx › Individual_data
Select a paper to view details